Travere Therapeutics (TVTX) Current Leases (2020 - 2026)
Travere Therapeutics' (TVTX) quarterly Current Leases came in at $6.0 million in Q1 2026, up 10.2% YoY from $5.5 million in Q1 2025, and up 2.42% on a QoQ basis from $5.9 million in Q4 2025.
Travere Therapeutics (TVTX) Current Leases (2020 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 7 years of Current Leases data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Current Leases rose 10.2% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 10.2% YoY) and the FY2025 annual result came in at $5.9 million, up 8.7% from the prior year.
- Current Leases rose to $6.0 million in Q1 2026, from $5.9 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $6.0 million in Q1 2026 to a low of $4.0 million in Q1 2022.
- A 5-year average of $5.0 million and a median of $5.0 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases rose 13.43% — and 2025, when it increased 8.25%.
- Tracing TVTX's Current Leases over 5 years: stood at $4.4 million in 2022, then rose by 10.74% to $4.9 million in 2023, then grew by 10.1% to $5.4 million in 2024, then grew by 8.7% to $5.9 million in 2025, then grew by 2.42% to $6.0 million in 2026.
- The last three Current Leases figures came in at $6.0 million (Q1 2026), $5.9 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.16 Mn |
| Mar 31, 2026 | 6.02 Mn |
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 5.41 Mn |
| Sep 30, 2024 | 5.30 Mn |
| Jun 30, 2024 | 5.16 Mn |
| Mar 31, 2024 | 5.04 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 4.78 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 4.55 Mn |
| Dec 31, 2022 | 4.43 Mn |
| Sep 30, 2022 | 4.23 Mn |
| Jun 30, 2022 | 4.12 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 3.91 Mn |
| Dec 31, 2020 | 357,000.00 |